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• Our example analysis extrapolated overall survival data from the COMPLEMENT-1 trial 4 • Double-blind, multicenter clinical trial of first-line treatment for chronic lymphocytic leukemia (CLL)
• Patients randomised to ofatumumab + chlorambucil (OCHL; n=221) or chlorambucil (CHL; n=226) and followed for a median 29 months • The survival rate was >70% at 4 years in both arms • Patient-level data from both trial arms were used in the present study • The external long-term follow-up study used to guide the extrapolation was the C9011 trial 5 • Patients randomised to CHL, fludarabine, or fludarabine + CHL for first-line treatment of CLL • Overall survival was reported for a period of about 18 years • The CHL arm (n=193) of trial C9011 was used for the present study to guide the extrapolation of the CHL arm of the COMPLEMENT-1 trial • The data could not be used directly as the overall survival rate over the first 4 years was markedly lower than observed for CHL in COMPLEMENT-1 • The disparity could be due to differences in patient population characteristics, the CHL dosing regimen, and/or general improvements in outcomes for cancer patients since the C9011 study cohort was enrolled (1990-1994) • The published Kaplan-Meier curve was digitised, and the graphical coordinates, together with the numbers at risk, were used to estimate a patient-level data set by the method of Guyot et al (2012) 6 • Long-term extrapolation for the overall survival in the COMPLEMENT-1 trial, guided by the C9011 data, was estimated using a staged approach • Stage 1: Parametric survival functions were fitted for the CHL arm in both studies with an indicator for study • Stage 2: The average treatment effect of OCHL vs CHL was estimated by survival analysis including data for both arms of COMPLEMENT-1 and the C9011 CHL arm, and including indicators for treatment and study. The coefficient for treatment from this model, which considered the shape of long-term survival for the CHL arm but allowed for study differences, provided an estimate of the treatment effect 
Results
Table 2. Overall Survival Predictions at 20 Years
• This work explored an approach to using external long-term follow-up data to guide the extrapolation of shorter-term trial survival data in situations where the external data cannot be used directly because outcomes differ between the studies during the follow-up period common to both studies • Conventional survival functions fitted to COMPLEMENT-1 data alone produced long-term predictions that appeared unlikely to be clinically plausible • For example, the Weibull function predicted a 20-year survival of 24% for the CHL arm • This estimate is much higher than clinical experience with CHL treatment for CLL based on expert opinion • In Step 1 of our analysis, three functions provided a reasonable fit to the CHL arms of both studies: Weibull, Gompertz, and gamma • One segment of the C9011 survival curve (between about 70 and 140 months) was poorly fitted by all parametric functions; the curve was irregular in this region and no attempt was made to achieve a closer fit because • The irregularities in the Kaplan-Meier were uncharacteristic of other survival curves for CLL patients • No study-specific or clinical explanation was identified • Possibly due to low patient numbers • In Step 2 the treatment effect for OCHL vs CHL was estimated, and in Step 3 this was applied to the functions fitted in Step 1. The resulting survival functions guided by the external C9011 data predicted markedly lower overall survival predictions than conventional functions fitted only to the COMPLEMENT-1 data • For example, the Weibull function predicted a 20-year survival of 8% for the CHL arm (versus 24% predicted by the conventional unguided functions) • Limitations
• The approach assumes proportional hazards (or accelerated failure time depending on the function fitted) between the study arms. The validity of this assumption after trial follow-up cannot be verified; however, for our example analysis there is no statistically significant evidence to suggest that this assumption is unreasonable during the common follow-up period • Using a more complex approach to more closely fit the C9011 data may have resulted in a different long-term extrapolation • The validity of the extrapolation cannot be verified without long-term observation of patient cohorts similar to that studied in COMPLEMENT-1 • Whether the treatment effect for OCHL vs CHL continues beyond the observed trial period is uncertain and cannot be verified without longer-term observation • Exploration of alternative scenarios regarding treatment benefit beyond trial follow-up is recommended 2 • In our analysis, overall survival at 20 years (Weibull function) was reduced from 12% to 8% when no treatment effect was assumed after 50 months
Results
• For comparison, Weibull functions fitted to the COMPLEMENT-1 data without any guidance by the C9011 data 5 are presented in Figure 4 (other functions were explored but are not shown) • This approach to using external long-term follow-up data to guide the extrapolation of shorter-term survival data could be of value in predicting survival for economic analyses • This approach may be particularly valuable if limited survival data are available and external data show differing outcomes • The approach may be useful for extrapolation of other time-to-event data • Care should be taken to
• Explore goodness-of-fit using accepted methods 2,3 and select functions which provide the best fit • Examine the validity of the proportional hazards assumption • Evaluate the clinical and biological plausibility of the long-term prediction
• In Stage 1, parametric survival functions were fitted for the CHL arm in both studies with an indicator for study. The results are presented in Table 1 and Figure 1 • Weibull, Gompertz, and gamma functions provided reasonable fits during trial follow-up and plausible extrapolations were assessed by AIC, BIC (Table 1) , visual inspection (Figure 1) , and expert clinical opinion • An example graphical diagnostic plot is shown in Figure 2 for the Weibull curve • The segment of the C9011 curve between about 70 and 140 months was poorly fitted by the curves; no attempt was made to achieve a closer fit to this data segment because the irregularities and undulations observed in the Kaplan-Meier data in this region are uncharacteristic of other overall survival curves for CLL patients (eg, see Woyach et al 7 ) , no study-specific or clinical explanation was identified, and it is possible that the relatively low patient numbers (n=193) account for the irregularities in the shape CHL, chlorambucil; CLL, chronic lymphocytic leukemia; K-M, Kaplan-Meier; OCHL, ofatumumab in combination with chlorambucil.
CHL, chlorambucil; CLL, chronic lymphocytic leukemia; C9011, long-term survival analysis of data from the C9011 study 5 ; K-M, Kaplan-Meier.
• In Stage 2, the average treatment effect for OCHL vs CHL was estimated from survival analysis of data from COMPLEMENT-1 (both arms) and C9011 (CHL arm), including indicators for treatment and study (data not shown) • In Stage 3, this estimate of the average treatment effect was used to modify the functions presented in Table 1 to create survival functions for OCHL • The resulting overall survival functions are presented in Figure 3 (only Weibull curves are shown for simplicity; curves were also fitted for the other functions)
CHL, chlorambucil; C9011, long-term survival analysis of data from Study C9011 5 ; OCHL, ofatumumab in combination with chlorambucil.
CHL, chlorambucil; CLL, chronic lymphocytic leukemia; C9011, long-term survival analysis of data from the C9011 study 5 ; K-M, Kaplan-Meier; OCHL, ofatumumab in combination with chlorambucil.
• Survival predictions guided by the external data were markedly lower than conventional functions fitted only to COMPLEMENT-1 data ( 
Discussion
Conflicts of Interest
EH, SW, and IP report funding from the GlaxoSmithKline group of companies to their employer, RTI Health Solutions, during the conduct of the study. AH was an employee of the GlaxoSmithKline group of companies during the conduct of the study.
AIC, Akaike information criterion; BIC, Bayesian information criterion; CHL, chlorambucil; COMP1, COMPLEMENT-1 trial; C9011, long-term survival analysis of data from the C9011 study 5 ; SE, standard error. 
